1. Home
  2. ABUS vs CDNL Comparison

ABUS vs CDNL Comparison

Compare ABUS & CDNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

N/A

Current Price

$3.74

Market Cap

836.0M

Sector

Health Care

ML Signal

N/A

Logo Cardinal Infrastructure Group Inc. Class A Common Stock

CDNL

Cardinal Infrastructure Group Inc. Class A Common Stock

N/A

Current Price

$15.29

Market Cap

888.6M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
ABUS
CDNL
Founded
2005
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
836.0M
888.6M
IPO Year
2008
2025

Fundamental Metrics

Financial Performance
Metric
ABUS
CDNL
Price
$3.74
$15.29
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
★ $47.25
AVG Volume (30 Days)
★ 2.3M
1.2M
Earning Date
11-20-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 55.26
N/A
EPS
★ 0.84
0.53
Revenue
$14,083,000.00
★ $456,045,369.00
Revenue This Year
$1,208.75
$95.00
Revenue Next Year
N/A
$24.54
P/E Ratio
★ $4.35
$27.04
Revenue Growth
★ 128.21
44.69
52 Week Low
$3.50
$12.51
52 Week High
$5.45
$96.40

Technical Indicators

Market Signals
Indicator
ABUS
CDNL
Relative Strength Index (RSI) 32.13 37.79
Support Level $3.50 $13.05
Resistance Level $4.53 $27.68
Average True Range (ATR) 0.18 1.21
MACD -0.04 0.68
Stochastic Oscillator 15.82 71.60

Price Performance

Historical Comparison
ABUS
CDNL

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

About CDNL Cardinal Infrastructure Group Inc. Class A Common Stock

Cardinal Infrastructure Group Inc provides a comprehensive suite of infrastructure services to the residential, commercial, industrial, municipal, and state infrastructure markets. The company provides wet utility installations (water, sewer, and stormwater systems), as well as grading, site clearing, erosion control, drilling and blasting, paving, and other related site services. It derives all revenue in the United States of America from construction projects based in North Carolina and South Carolina.

Share on Social Networks: